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 FOREWORD 
 
The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Purchasing 
Authorities Chief Executives (PACE) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development, The Scottish Health Purchasing Information Centre 
(SHPIC) and The University of Birmingham Institute for Public and Environmental Health. 
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EXECUTIVE SUMMARY 
 
Spinal Cord Stimulation (SCS) is ‘.... a reversible, non-ablative technique for the 
management of intractable pain’.
1
 Over time there has been little agreement about the 
indications for the use of SCS. Clinical use has been based more on uncontrolled 
experience than controlled trials.  
 
Although the volume of activity is not large (approximately 30 procedures were carried out in 
the Yorkshire Region in 1996) the treatment package, including testing, implant and follow-
up, has been costed at between £7,500 and around £9,000. This level of expenditure can 
only be supported if there is strong evidence of clinical benefit.  
 
 This paper considers the evidence for the effectiveness of SCS in the following conditions: 
‘failed back surgery syndrome’ (FBSS); peripheral vascular disease (PVD) with ischaemic 
pain; peripheral nerve injury (PNI); phantom limb or stump pain; spinal cord lesions with well 
circumscribed segmental pain; and angina pectoris.  
  
 The quality of evidence is generally weak. The best evidence of efficacy is for PVD and 
angina pectoris. The preliminary report of the RCT in FBSS suggests that there is potential 
benefit from SCS in this condition. For all other indications the existing evidence is very 
poor. The poor quality of the evidence is a reflection of the difficulties in carrying out RCTs; 
these difficulties include recruiting from a heterogeneous group of patients each with very 
low numbers and little agreement about best practice. 
 
There is insufficient evidence to estimate the cost-effectiveness of SCS in any of these 
conditions. There is sufficient evidence to justify additional well designed research in most of 
them. However, it is difficult to justify purchasing SCS from mainstream NHS funds except 
for PVD, angina pectoris and possibly certain types of FBSS.  
 
If SCS is to be purchased, it should be from a single designated provider, to maximise 
expertise, and should include proper assessment and collection of outcome data to inform 
future decision making. 
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1. INTRODUCTION 
 
Spinal Cord Stimulation (SCS) is ‘.... a reversible, non-ablative technique for the 
management of intractable pain’.
1
 First used in America in 1967, it involves the electrical 
stimulation of the spinal cord via a device which may be implanted by surgical or 
percutaneous procedures. These devices can be driven by an intracorporeal powered pulse 
generator or by an external transmitter and radio frequency coupling. Early designs 
consisted of monopolar electrodes, but modern equipment tends to have multiple electrodes 
which are more effective and optimise stimulation in varying body positions. 
 
Over time there has been little agreement about the indications for the use of SCS. Clinical 
use has been based more on uncontrolled experience than controlled trials. Failure rates for 
pain relief have been high
1
 as have complication rates.
2
  Increasingly, there is agreement on 
the need to select patients carefully as certain types of chronic pain are proving more 
amenable than others to successful management using SCS. 
 
The volume of activity is not large; approximately 30 procedures were carried out in the 
Yorkshire Region in 1996, (personal communication from Dr. R. Marks; York District 
General Hospital). However, the treatment package including testing, implant and follow-up 
has been costed at around £7,500 to £9,000. This level of expenditure can only be 
supported if there is strong evidence of clinical benefit.  
 
The objectives of this paper are: 
(a) to review the evidence on the effectiveness of SCS in the treatment of different types of 
chronic pain;  
(b) to summarise what agreement there is on the most appropriate applications of SCS; and  
(c) to outline possible options for purchasers to consider with regard to funding SCS in the 
future. 
 
The terms ‘Spinal Cord Stimulation’ and ‘Dorsal Column Stimulation’ are used 
interchangeably in the literature. This paper will use the term ‘Spinal Cord Stimulation’ 
(SCS). 
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2. SPINAL CORD STIMULATION IN THE MANAGEMENT OF CHRONIC 
 PAIN: SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1 Summary of Evidence of Effectiveness 
 
North
3
 gives the following list of conditions for which SCS has been recommended: 
“... listed in decreasing order of frequency of application and reported success rates. 
1. Lumbar arachnoid fibrosis or ‘failed back surgery syndrome’ (FBSS) with radiculopathic 
pain, ideally predominating over axial low back pain, in particular mechanical pain. 
2. Peripheral vascular disease (PVD), with ischaemic pain. 
3. Peripheral nerve injury (PNI), neuralgia, causalgia (including so called ‘reflex 
sympathetic dystrophy’). 
4. Phantom limb or stump pain. 
5. Spinal cord lesions, with well circumscribed segmental pain”.
 
 
 
Simpson
1
 gives a much more extensive list (See Table 1 below). However, there is only one 
condition, angina pectoris, which Simpson considers appropriate for SCS, which is not 
included in North’s list. The remainder of the paper will therefore limit itself to considering 
the five conditions identified by North, plus angina pectoris.  
Table 1: Simpson’s Review of Success with SCS Based on Reports  
  Published between 1981-1994 
  GROUP LEVEL OF SUCCESS 
A Success almost certain  
Angina pectoris    Ischaemic limb pain 
B Success very likely 
Causalgia     Cauda equina damage 
Reflex sympathetic dystrophy   Nerve root avulsion 
Peripheral nerve lesion    Amputation stump pain 
Brachial plexus damage 
C Success reasonably likely 
Failed back surgery syndrome   Phantom limb pain 
(leg pain more than back pain)    
Partial spinal cord lesion   Post herpetic neuralgia 
D Success unlikely 
Nociceptive pain, including cancer  Vaginal, penile, rectal, perianal pain 
Thalamic syndrome    Other mid-line pains 
(central post-stroke pain) 
Intercostal neuralgia 
E Success very unlikely 
Facial anaesthesia dolorosa   Abdominal pain 
Atypical facial pain    Complete cord lesion 
The criteria which Simpson uses to categorise these conditions are not made clear in the 
paper.
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1. Lumbar Arachnoid Fibrosis - ‘Failed Back Surgery Syndrome’ . 
 
Failed back surgery syndrome (FBSS) is not a single disease entity, and a fundamental 
distinction exists between FBSS with purely back pain, and FBSS with back and leg pain. 
Simpson suggests that the outcome (in terms of pain relief) of SCS for FBSS with back and 
leg pain is superior to that when used for back pain alone.
2
 The evidence on the efficacy of 
FBSS is generally from data reported as part of case series containing patients with various 
conditions.
2
 There is an on-going randomised controlled trial (RCT)
3
 which has reported 
initial results. This study is a randomised cross-over trial of somewhat unusual design. 
Patients are randomised between re-operation and SCS for the management of FBSS. Six 
months after the initial intervention, the patients are offered the opportunity to choose to 
switch to the alternative intervention. Preliminary results indicate that more of the patients 
who underwent surgery as the initial intervention chose to switch to SCS after six months. 
This suggests that FBSS has better patient perceived outcomes with SCS than re-operation. 
However, at the present time, there is no definitive evidence for the efficacy of SCS in 
treating FBSS. 
 
2. Peripheral Vascular Disease 
 
A number of case series have reported improvements in the pain and functioning of people 
suffering from PVD, specifically critical limb ischaemia.
2,4,5
  Other reported benefits include 
healing of ulcers and improved microvascular blood flow.  
 
As before, the datasets on which these reports are based tend to be small and have often 
been collected over a number of years, during which time the technology and the level of 
clinical expertise has changed, making it difficult to view them as a single sample.  
 
Simpson
1
 reports two studies on-going in the United States and Sweden which are designed 
to provide clear evidence on the effectiveness or otherwise of SCS in treating PVD. They 
were due to have reported at the end of 1994, but no published results have been identified 
in the literature. A personal communication from Professor Jacobs in Amsterdam, the lead 
clinician for the Swedish Study, indicates that the initial results suggest a benefit from SCS. 
However, the Dutch authorities are asking for outcome data at two years before making a 
definitive decision on re-imbursment.  
 
3. Peripheral Nerve Injury 
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 Simpson
1
 identifies nine papers, published between 1981 and 1991, which he claims report 
good outcomes for SCS in the treatment of PNI with SCS being particularly effective with 
regard to reducing pain and immobility. However, these conclusions do not appear to be 
consistent with the evidence presented. 
  
 As with the rest of the literature on SCS, the literature on its use in PNI does not include RCTs, 
nor even particularly large case series. The evidential basis for using SCS in PNI, therefore, 
remains poor. 
  
4. Phantom Limb or ‘Stump’ Pain. 
  
 Simpson
1
 identified 69 papers reporting the use of SCS for chronic pain. It is quite telling that 
in his review of the efficacy of SCS in phantom limb pain, he does not cite a single paper in 
support of his arguments. The authors of this paper have managed to identify one paper by 
Krainick et al reporting the outcome of SCS for pain reduction in amputees.
6
 This paper 
states that 42.6% of the 64 patients studied, had pain relief of 25% or more at five year 
follow-up. What the authors do not make clear is how pain relief was measured and, 
therefore, what 25% means. 
  
Once again, the evidence for the efficacy of SCS must be considered poor.  
 
5. Spinal Cord Lesions, with well Circumscribed Segmental Pain 
  
 The literature on the use of SCS for the management of pain related to spinal cord lesions 
tends to report failure. Simpson
1 
 suggests that this may be because spinal cord lesions are 
a heterogeneous group  of conditions, none of which is sufficiently well understood to allow 
the effective use of SCS. 
  
6. Angina Pectoris 
  
 SCS for intractable angina was first used by Murphy and Giles in 1987,
7
 since when many 
other reports have been published.
2
 Murphy and Giles’ consistently repeated finding was 
that SCS reduced both the frequency and the severity of attacks in all 10 patients studied. 
Other reports have reported improvements in exercise tolerance, reduced pain from angina 
and decreased recovery time.
8
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 Extensive experimental work has failed to identify any negative side effects of SCS in the 
treatment of angina pectoris.
9,10
  
  
 The weight and quality of the evidence for the effectiveness of SCS in the treatment of angina 
pectoris is greater than for any other proposed use. This said, there is still no definitive RCT 
of SCS in angina pectoris published to date.
11 
  
 Table 3 describes, from a small review of the literature, the type of study reported and the 
quality of the evidence contained therein. The scoring system is set out in Table 2. 
  
 2.2 Conclusion on the Quality of Evidence 
  
 The overall quality of evidence is generally weak. Although all the papers cited in Table 3 
are categorised as either III or IV, the best evidence of efficacy is for PVD and angina 
pectoris. In these two indications, there is laboratory confirmation of improved micro-
vascular supply and improvement in more objective outcome measures such as stress tests, 
recovery time and healing of ulcers. The preliminary report of the RCT in FBSS suggests 
that there is potential benefit from SCS in this condition, but this trial has not yet reported 
fully. For all other indications the existing evidence is very poor.  
  
 A recent Health Technology Assessment of Chronic Pain Control offered in an out-patient 
setting concluded that - for back pain: “there is a lack of evidence supporting the use of 
spinal cord stimulators. Case series are of poor quality and do not provide evidence of 
effectiveness, although at least 50% pain relief at five years is reported in over 50% of 
patients.”
12 
  
 The poor quality of the evidence must be judged in the context of the difficulties of setting up 
RCTs in this area: 
  
 The number of patients suitable for SCS in any one condition is small; 
 There are significant variations in practice with regard to assessment and trial 
stimulation, making pooling of data from different centres difficult; 
 There are relatively few well validated measures for assessing pain, the main outcome 
of treatment; 
 7 
 The hardware has developed significantly over time. Thus, the long time period required 
to recruit sufficient patients carries the risk of the results being obsolete by the time they 
are available. 
  
 Given the poor quality of evidence for benefit from SCS in most of these conditions, and that 
most of the conditions have case series reporting some benefit, it is reasonable to conclude 
that further research can be justified. However, it is probably difficult to argue that the 
money should come from main stream NHS funding for any conditions other than PVD and 
angina pectoris. 
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 Table 2:  Classification of the Quality of Evidence
13
 
  
 I  Evidence obtained from at least one properly designed randomised controlled 
  trial. 
  
 II-1  Evidence obtained from well designed controlled trials without randomisation. 
  
 II-2  Evidence obtained from well designed cohort or case controlled analytic  
  studies, preferably from more than one centre or research group. 
  
 II-3  Evidence obtained from multiple time series with or without the intervention, 
  or from dramatic results in uncontrolled experiments. 
  
 III  Opinions of respected authorities based on clinical experience, descriptive 
  studies or reports of expert committees. 
  
 IV  Evidence inadequate owing to problems of methodology, e.g. sample size, 
  length or comprehensiveness of follow-up, or conflict in evidence. 
  
 Table 3: Quality of Published Evidence on the Effectiveness of   
  SCS for Different Types of Chronic Pain 
  
PAPER
 
TYPE OF STUDY QUALITY OF  EVIDENCE 
(see Table 2 above) 
North RB. The role of spinal cord simulation 
in contemporary pain management. APS 
Journal 1993; 2: 91-99. 
Narrative review of the 
literature on SCS for 
chronic pain relief. 
III 
Simpson BA. Spinal cord stimulation. Pain 
Reviews 1994; 1: 199-230. 
Narrative literature review 
of SCS in chronic pain 
management. 
III 
Urban BJ, Nashold BS. Percutaneous 
epidural stimulation of the spinal cord for 
relief of pain. Journal of Neurosurgery 1978; 
48: 323-328. 
Reports results of SCS 
for chronic pain in 20 
patients at up to 2 years 
post implantation. 
III 
North RB, Kidd DH, Lee MS et al. A 
prospective RCT of spinal cord stimulation 
versus reoperation for FBSS: Initial result.    
Stereoatactic and Functional Neurosurgery 
1994: 62; 267-272.  
Reports initial results, for 
the first 27 patients, of a 
RCT for SCS in FBSS.  
IV at present, but when 
full trial reports this may 
improve the quality of 
evidence 
Jacobs MJHM, Jorning PJG, Beckers RCY et 
al. Foot salvage and improvement of 
microvascular blood flow as a result of 
epidural spinal cord electrical stimulation. 
Journal of Vascular Surgery 1990; 12: 654-
60. 
Reports effect of SCS on 
microcirculatory blood 
flow for case series of 20 
patients. 
III 
Krainick J, Thoden U, Riechart T. Pain 
reduction in amputees by long term spinal 
cord stimulation. Journal of Neurosurgery 
1980; 52: 346-350. 
Reports effects of SCS on 
pain relief for 64 
amputees at two year 
follow-up. 
IV 
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North RB, Kidd DH, Zahwak M et al. Spinal 
cord stimulation for chronic intractable pain: 
experience over two decades. Neurosurgery 
1993 ;32: 63-67. 
Reports the effects of 
SCS for chronic pain 
management in 320 
patients over 20 years. 
III 
Augustinsson LE, Holdm J, Carlsson CA et 
al. Epidural electrical stimulation in severe 
limb ischaemia. Evidence of pain relief, 
increased blood flow  and a possible limb 
saving effect. Annals of Surgery 1985; 202: 
104-111. 
Reports effect of SCS in 
PVD for 34 patients over 7 
years. Follow-up up to 16 
months. 
III 
Eliasson T, Augustinsson LE, Mannheimer 
C.  Spinal cord stimulation in severe angina 
pectoris - presentation of current studies, 
indications and clinical experience. Pain 
1996; 65: 169-179. 
Narrative review of  
literature from 1980s and 
1990s on use of SCS in 
angina pectoris. 
III 
de Jongste MJL Hautvast RWM Hillege HL  
Lie KI Efficacy of Spinal Cord Stimulation as 
Adjuvant Therapy for Intractable Angina 
Pectoris: A prospective RCT. Journal of the 
American College of Cardiology 1994; 23: 
1592-7. 
Reports a RCT of SCS in 
the management of 
angina pectoris with 8 
week follow-up, for 17 
patients.  
IV 
 
 
 2.3 Patient Selection and Effectiveness 
  
 Initially, patients were selected for SCS on the basis of the severity and/or the chronicity of 
their condition. However, the low success rates, the invasive nature of the treatment and the 
difficulty in obtaining funding, focused attention on ways of identifying those patients with the 
greater probability of successful outcomes. 
  
 A large body of work has looked at the possible role of psychiatric screening to exclude patients 
with ‘psychiatric disturbance’ or ‘serious mental disability’. However, this body of work has 
failed to produce a definitive conclusion as to its value, and it is by no means standard 
practice. 
2
 
  
 Some researchers have suggested that success is related to the ‘quality’ of the pain. North et 
al. have shown that success is positively related to pain being described as ‘sharp’; and that 
a poor outcome is related to pain being described as ‘pounding’ or ‘sickening’.
14
 Despite 
this, the actual use of validated instruments which describe the type of pain, (e.g. McGill 
Pain Questionnaire) in relation to SCS, is surprisingly rare. The effect of this is that the 
hypothesis has never been properly tested. However, it is important to note that outcome for 
patients with chronic pain may be poorly assessed by monitoring pain and disability alone. 
Measurements of quality of life and return to work, for example, may be better indicators of 
successful treatment. 
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 Trial cord stimulation, where a temporary percutaneous system is used to assess the efficacy of 
SCS for the individual patient, was initially expected to become a routine part of the 
treatment process.
2
 However, significant variation in the published results on the efficacy of 
trial stimulation has meant that this has not been the case. Failure rates in series using trial 
stimulation appear little different from failure rates in series which do not use trial 
stimulation.
2
 
 
2.4 Complications 
 
The most common complications have been associated with hardware failure, electrode 
migration and dislodgement, lead fracture and current leakage. These have become less 
common as the equipment has developed and clinicians have gained experience in the 
implantation procedures. 
 
Infection rates vary enormously, with variations between temporary and permanent systems 
and the type of system. The incidence of reported infection is between 3% and 5%.
3 
 
Infections are either (a) superficial around the pulse generator, or (b) more serious in the 
epidural space e.g. epidural abscess. 
 
Post-operative pain is also a well recognised, but poorly documented, complication of 
surgical implantation. On the basis of personal communications with surgeons using the 
procedure, Simpson estimates that 5-10% of patients experience post-operative pain after 
thoracic laminectomy, which can last for several weeks. Percutaneous implantation is less 
painful. 
 
Cord compression was reported in the early series, however, the numbers reported were 
small and the deficits usually reversible. Transient or reversible neurological deficit, not due 
to compression, has also been reported, but again not in large numbers. 
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 3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
  
 The Royal Hallamshire Hospital, Sheffield, charges £9,000 for SCS treatment, which 
includes testing, implant and follow-up. The Leicester Royal Infirmary and Guy’s Hospital, 
London charge £7,500 for a similar package of care. Cost savings will predominantly be in 
relation to analgesia prescriptions. For angina pectoris there may be savings from a 
reduction in in-patient admissions as a result of the reduction in the number of angina 
attacks. A key determinant of the relative cost of SCS and traditional analgesia treatment is 
likely to be the effective life-time of each implant. The more frequent the need for 
replacement, the less likely it is that SCS will be a net cost-saving intervention. 
Manufacturers currently estimate the lifespan of SCS hardware to be five years.  However, 
this will vary between components and is also dependent on the amount of usage. 
  
 The paucity of high quality evidence on the effectiveness of SCS has been documented 
above. At the present time, the published data do not allow a quantitative comparison of the 
costs and benefits of SCS. 
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 4. OPTIONS FOR PURCHASERS AND PROVIDERS 
  
Option 1 Stop/do not purchase.  
  
Option 2 Purchase SCS for angina pectoris and PVD. Await the result of the RCT for 
FBSS before purchasing SCS for this indication. 
  
Option 3 Purchase SCS for angina pectoris, peripheral vascular disease and FBSS. 
  
Option 4 Option 3 but purchase SCS for FBSS on a case by case basis, using strict 
patient criteria for selection and assessment. 
  
Option 5 Purchase any of the options above only within a properly designed trial 
incorporating an economic evaluation. 
  
Option 6 Purchase all categories on request. 
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5.  DISCUSSION AND CONCLUSION 
 
There are no UK trials of SCS presently on-going. The primary option would be for 
purchasers to push for the establishment of such a trial (or programme of trials), and 
possibly to purchase SCS treatment only within the context of such a trial(s).  
 
The evidence base for purchasing SCS is weak. The use of SCS should ideally be part of a 
well designed trial. The poor quality of the evidence is, however, a reflection of the difficulty 
of carrying out RCTs in small patient groups, and where there is little agreement about what 
should be the exact intervention to be evaluated. 
 
If purchasers are to fund SCS there is a need to agree patient criteria. These could possibly 
include criteria for the quality of pain and the success of the trial stimulation. In addition, 
instruments to measure outcome should be adopted by the provider and complications 
monitored. 
 
Permanent SCS should be implanted by a limited number of designated providers as the 
number of patients who might be suitable for SCS is very small, even when they are 
aggregated to a regional level. Therefore, it seems sensible to limit the number of provider 
units, so that the skills of the provider unit can be developed and thereby the complication 
rates minimised. A further benefit of limiting the number of provider units is that it will make 
evaluation easier. 
 
Although there is slightly stronger evidence for use in PVD and angina pectoris, FBSS 
patients are likely to be the largest patient category for which SCS is requested. Patients 
with FBSS have often had a number of previous interventions to relieve their pain. The role 
of SCS in this group could be considered a possible option, but only in the context of a ‘last 
resort’ treatment. If purchasers wish to consider SCS for this group of patients, specific 
patient criteria may include: 
 
 FBSS patients should have leg pain, not spinal pain alone; 
 Patients should have prior assessment by spinal and pain specialists to consider/exclude 
other options. This should include an assessment of the quality of pain; 
 Trial of stimulation by the designated provider should always be performed and be 
successful to warrant a permanent SCS. 
 14 
These criteria should be revised following the report of the RCT referred to earlier in the 
text.  
 
The purchase of SCS for peripheral nerve injury, phantom pain, and spinal cord lesions in 
well circumscribed segmental pain, is hard to justify on the basis of expected health gain 
predicted from the published evidence. 
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6. SPINAL CORD STIMULATION IN THE MANAGEMENT OF CHRONIC PAIN : SUMMARY MATRIX 
PATIENT 
GROUP 
PATIENT CRITERIA 
(GUIDELINES NOT 
PROTOCOLS) 
ESTIMATED 
FUTURE 
ACTIVITY 
OPPORTUNITY 
FOR COST 
SAVING 
AUDIT POINTS EFFECTS THAT 
COULD BE 
EXPECTED IN 
RELATION TO 
STARTING POINT 
COST-
EFFECTIVENESS 
Angina Pectoris 
 
 
 
 
 
PVD 
 
 
 
 
FBSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL 
 
Not responding to 
medication and not suitable 
for surgical treatment 
 
 
 
As above 
(Review following report of 
RCT) 
 
 
Patients with: leg pain; sharp 
quality of pain; prior 
assessment by spinal and 
pain specialists 
 
Trial successful 
 
Review  criteria following 
reporting  of RCT 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~5 for a HA of 
500,000  
Reduced analgesia 
Reduced 
admissions 
 
 
 
Reduced analgesia 
Reduced 
admissions 
 
 
Reduced analgesia 
Reduced surgery 
 
 
Restrict number of 
providers 
1. The number 
of procedures 
per specialist. 
 
2. Compliance 
with patient 
criteria. 
 
3. Complication 
rate. 
 
4. Monitor 
success by 
measuring 
outcome for 
quality of life, 
pain and 
disability using 
validated 
instruments as 
well as 
measures of:  
 
i) successful 
trial of 
treatment; 
 
ii) successful 
permanent 
implant. 
 Not available 
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